23.12
-0.24 (-1.03%)
| Penutupan Terdahulu | 23.36 |
| Buka | 22.98 |
| Jumlah Dagangan | 357,858 |
| Purata Dagangan (3B) | 657,019 |
| Modal Pasaran | 1,701,029,632 |
| Harga / Pendapatan (P/E Ke hadapan) | 24.69 |
| Harga / Jualan (P/S) | 22.85 |
| Harga / Buku (P/B) | 11.10 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Keuntungan | -121.73% |
| Margin Operasi (TTM) | -94.48% |
| EPS Cair (TTM) | -1.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 170.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.68% |
| Nisbah Semasa (MRQ) | 4.71 |
| Aliran Tunai Operasi (OCF TTM) | -75.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.20 M |
| Pulangan Atas Aset (ROA TTM) | -13.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -29.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Zymeworks Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -3.5 |
| Purata | -1.50 |
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.15% |
| % Dimiliki oleh Institusi | 102.76% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Capricorn Fund Managers Ltd | 31 Mar 2026 | 1,007,210 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |